Physician profile
Tom Roark
NPI 1407895709
$1,269.47
in general payments reported to CMS, 2019-2025
13 companies · $98.67 in 2025
The $98.67 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $43.94 · 2021: $181 · 2022: $213 · 2023: $422 · 2024: $129 · 2025: $98.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.54 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.38 | 2021-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $240.01 | 2019-2023 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.63 | 2019 | |
| Dermavant Sciences, INC. | $87.13 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $56.01 | 2024 | |
| Pfizer INC. | $44.07 | 2022-2023 | |
| Journey Medical Corporation | $40.34 | 2019-2020 | |
| Lilly USA, LLC | $35.41 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $31.59 | 2023-2024 | Odomzo, Blu-U |
| Genzyme Corporation | $25.39 | 2022 | |
| Elekta, INC. | $23.93 | 2025 | Flexitron Hdr |
| Organon LLC | $23.78 | 2023 | Hadlima |
| Amgen INC. | $18.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Roark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.